This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bazmi, H. Z.
Right arrow Articles by Mellors, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bazmi, H. Z.
Right arrow Articles by Mellors, J. W.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ZIDOVUDINE

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2000, p. 1783-1788, Vol. 44, No. 7
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

In Vitro Selection of Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Decrease Susceptibility to (-)-beta -D-Dioxolane-Guanosine and Suppress Resistance to 3'-Azido-3'-Deoxythymidine

Holly Z. Bazmi,1 Jennifer L. Hammond,1 Socrates C. H. Cavalcanti,2 Chung K. Chu,2 Raymond F. Schinazi,3 and John W. Mellors1,4,5,*

Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh,1 Department of Medicine, University of Pittsburgh School of Medicine,4 and Veterans Affairs Medical Center,5 Pittsburgh, Pennsylvania; Center for Drug Discovery and Department of Pharmaceutical and Biochemical Sciences, University of Georgia, Athens, Georgia2; and Department of Pediatrics, Emory University School of Medicine, and the Georgia Veterans Affairs Research Center on AIDS and HIV Infection, Veterans Affair Medical Center, Decatur, Georgia3

Received 28 October 1999/Returned for modification 22 February 2000/Accepted 20 March 2000

Human immunodeficiency virus type 1 (HIV-1) isolates resistant to (-)-beta -D-dioxolane-guanosine (DXG), a potent and selective nucleoside analog HIV-1 reverse transcriptase (RT) inhibitor, were selected by serial passage of HIV-1LAI in increasing drug concentrations (maximum concentration, 30 µM). Two independent selection experiments were performed. Viral isolates for which the DXG median effective concentrations (EC50s) increased 7.3- and 12.2-fold were isolated after 13 and 14 passages, respectively. Cloning and DNA sequencing of the RT region from the first resistant isolate identified a K65R mutation (AAA to AGA) in 10 of 10 clones. The role of this mutation in DXG resistance was confirmed by site-specific mutagenesis of HIV-1LAI. The K65R mutation also conferred greater than threefold cross-resistance to 2',3'-dideoxycytidine, 2',3'-dideoxyinosine, 2',3'-dideoxy-3'-thiacytidine, 9-(2-phosphonylmethoxyethyl)adenine, 2-amino-6-chloropurine dioxolane, dioxolanyl-5-fluorocytosine, and diaminopurine dioxolane but had only marginal effects on 3'-azido-3'-deoxthymidine (AZT) susceptibility. However, when introduced into a genetic background for AZT resistance (D67N, K70R, T215Y, T219Q), the K65R mutation reversed the AZT resistance. DNA sequencing of RT clones derived from the second resistant isolate identified the L74V mutation, previously reported to cause ddI resistance. The L74V mutation also decreased the AZT resistance when the mutation was introduced into a genetic background for AZT resistance (D67N, K70R, T215Y, T219Q) but to a lesser degree than the K65R mutation did. These findings indicate that DXG and certain 2',3'-dideoxy compounds (e.g., ddI) can select for the same resistance mutations and thus may not be optimal for use in combination. However, the combination of AZT with DXG or its orally bioavailable prodrug (-)-beta -D-2,6-diaminopurine-dioxolane should be explored because of the suppressive effects of the K65R and L74V mutations on AZT resistance.

* Corresponding author. Mailing address: 603 Parran Hall, Graduate of School of Public Health, University of Pittsburgh, 130 DeSoto St., Pittsburgh, PA 15261. Phone: (412) 624-8512. Fax: (412) 383-7982. E-mail: mellors{at}msx.dept-med.pitt.edu.

Antimicrobial Agents and Chemotherapy, July 2000, p. 1783-1788, Vol. 44, No. 7
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Hurwitz, S. J., Asif, G., Kivel, N. M., Schinazi, R. F. (2008). Development of an Optimized Dose for Coformulation of Zidovudine with Drugs That Select for the K65R Mutation Using a Population Pharmacokinetic and Enzyme Kinetic Simulation Model. Antimicrob. Agents Chemother. 52: 4241-4250 [Abstract] [Full Text]  
  • Frangeul, A., Barral, K., Alvarez, K., Canard, B. (2007). In Vitro Suppression of K65R Reverse Transcriptase-Mediated Tenofovir- and Adefovir-5'-Diphosphate Resistance Conferred by the Boranophosphonate Derivatives. Antimicrob. Agents Chemother. 51: 3162-3167 [Abstract] [Full Text]  
  • Parikh, U. M., Bacheler, L., Koontz, D., Mellors, J. W. (2006). The K65R Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Exhibits Bidirectional Phenotypic Antagonism with Thymidine Analog Mutations.. J. Virol. 80: 4971-4977 [Abstract] [Full Text]  
  • Hammond, J. L., Parikh, U. M., Koontz, D. L., Schlueter-Wirtz, S., Chu, C. K., Bazmi, H. Z., Schinazi, R. F., Mellors, J. W. (2005). In Vitro Selection and Analysis of Human Immunodeficiency Virus Type 1 Resistant to Derivatives of {beta}-2',3'-Didehydro-2',3'-Dideoxy-5-Fluorocytidine. Antimicrob. Agents Chemother. 49: 3930-3932 [Abstract] [Full Text]  
  • Wainberg, M. A., Brenner, B. G., Turner, D. (2005). Changing Patterns in the Selection of Viral Mutations among Patients Receiving Nucleoside and Nucleotide Drug Combinations Directed against Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrob. Agents Chemother. 49: 1671-1678 [Full Text]  
  • Parikh, U. M., Koontz, D. L., Chu, C. K., Schinazi, R. F., Mellors, J. W. (2005). In Vitro Activity of Structurally Diverse Nucleoside Analogs against Human Immunodeficiency Virus Type 1 with the K65R Mutation in Reverse Transcriptase. Antimicrob. Agents Chemother. 49: 1139-1144 [Abstract] [Full Text]  
  • Borroto-Esoda, K., Myrick, F., Feng, J., Jeffrey, J., Furman, P. (2004). In Vitro Combination of Amdoxovir and the Inosine Monophosphate Dehydrogenase Inhibitors Mycophenolic Acid and Ribavirin Demonstrates Potent Activity against Wild-Type and Drug-Resistant Variants of Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 48: 4387-4394 [Abstract] [Full Text]  
  • Hofman, M. J., Higgins, J., Matthews, T. B., Pedersen, N. C., Tan, C., Schinazi, R. F., North, T. W. (2004). Efavirenz Therapy in Rhesus Macaques Infected with a Chimera of Simian Immunodeficiency Virus Containing Reverse Transcriptase from Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 48: 3483-3490 [Abstract] [Full Text]  
  • Gallant, J. E., Staszewski, S., Pozniak, A. L., DeJesus, E., Suleiman, J. M. A. H., Miller, M. D., Coakley, D. F., Lu, B., Toole, J. J., Cheng, A. K., for the 903 Study Group, (2004). Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A 3-Year Randomized Trial. JAMA 292: 191-201 [Abstract] [Full Text]  
  • Stone, C., Ait-Khaled, M., Craig, C., Griffin, P., Tisdale, M. (2004). Human Immunodeficiency Virus Type 1 Reverse Transcriptase Mutation Selection during In Vitro Exposure to Tenofovir Alone or Combined with Abacavir or Lamivudine. Antimicrob. Agents Chemother. 48: 1413-1415 [Abstract] [Full Text]  
  • Selmi, B., Deval, J., Alvarez, K., Boretto, J., Sarfati, S., Guerreiro, C., Canard, B. (2003). The Y181C Substitution in 3'-Azido-3'-deoxythymidine-resistant Human Immunodeficiency Virus, Type 1, Reverse Transcriptase Suppresses the ATP-mediated Repair of the 3'-Azido-3'-deoxythymidine 5'-Monophosphate-terminated Primer. J. Biol. Chem. 278: 40464-40472 [Abstract] [Full Text]  
  • Jeffrey, J. L., Feng, J. Y., Qi, C. C. R., Anderson, K. S., Furman, P. A. (2003). Dioxolane Guanosine 5'-Triphosphate, an Alternative Substrate Inhibitor of Wild-type and Mutant HIV-1 Reverse Transcriptase: STEADY STATE AND PRE-STEADY STATE KINETIC ANALYSES. J. Biol. Chem. 278: 18971-18979 [Abstract] [Full Text]  
  • Garcia-Lerma, J. G., MacInnes, H., Bennett, D., Reid, P., Nidtha, S., Weinstock, H., Kaplan, J. E., Heneine, W. (2003). A Novel Genetic Pathway of Human Immunodeficiency Virus Type 1 Resistance to Stavudine Mediated by the K65R Mutation. J. Virol. 77: 5685-5693 [Abstract] [Full Text]  
  • Kewn, S., Wang, L. H., Hoggard, P. G., Rousseau, F., Hart, R., MacNeela, J. P., Khoo, S. H., Back, D. J. (2003). Enzymatic Assay for Measurement of Intracellular DXG Triphosphate Concentrations in Peripheral Blood Mononuclear Cells from Human Immunodeficiency Virus Type 1-Infected Patients. Antimicrob. Agents Chemother. 47: 255-261 [Abstract] [Full Text]  
  • Murry, J. P., Higgins, J., Matthews, T. B., Huang, V. Y., Van Rompay, K. K. A., Pedersen, N. C., North, T. W. (2002). Reversion of the M184V Mutation in Simian Immunodeficiency Virus Reverse Transcriptase Is Selected by Tenofovir, Even in the Presence of Lamivudine. J. Virol. 77: 1120-1130 [Abstract] [Full Text]  
  • White, K. L., Margot, N. A., Wrin, T., Petropoulos, C. J., Miller, M. D., Naeger, L. K. (2002). Molecular Mechanisms of Resistance to Human Immunodeficiency Virus Type 1 with Reverse Transcriptase Mutations K65R and K65R+M184V and Their Effects on Enzyme Function and Viral Replication Capacity. Antimicrob. Agents Chemother. 46: 3437-3446 [Abstract] [Full Text]  
  • Schinazi, R. F., Mellors, J., Bazmi, H., Diamond, S., Garber, S., Gallagher, K., Geleziunas, R., Klabe, R., Pierce, M., Rayner, M., Wu, J.-T., Zhang, H., Hammond, J., Bacheler, L., Manion, D. J., Otto, M. J., Stuyver, L., Trainor, G., Liotta, D. C., Erickson-Viitanen, S. (2002). DPC 817: a Cytidine Nucleoside Analog with Activity against Zidovudine- and Lamivudine-Resistant Viral Variants. Antimicrob. Agents Chemother. 46: 1394-1401 [Abstract] [Full Text]  
  • Selmi, B., Boretto, J., Sarfati, S. R., Guerreiro, C., Canard, B. (2001). Mechanism-based Suppression of Dideoxynucleotide Resistance by K65R Human Immunodeficiency Virus Reverse Transcriptase Using an alpha -Boranophosphate Nucleoside Analogue. J. Biol. Chem. 276: 48466-48472 [Abstract] [Full Text]  
  • Hammond, J. L., Koontz, D. L., Bazmi, H. Z., Beadle, J. R., Hostetler, S. E., Kini, G. D., Aldern, K. A., Richman, D. D., Hostetler, K. Y., Mellors, J. W. (2001). Alkylglycerol Prodrugs of Phosphonoformate Are Potent In Vitro Inhibitors of Nucleoside-Resistant Human Immunodeficiency Virus Type 1 and Select for Resistance Mutations That Suppress Zidovudine Resistance. Antimicrob. Agents Chemother. 45: 1621-1628 [Abstract] [Full Text]  
  • Furman, P. A., Jeffrey, J., Kiefer, L. L., Feng, J. Y., Anderson, K. S., Borroto-Esoda, K., Hill, E., Copeland, W. C., Chu, C. K., Sommadossi, J.-P., Liberman, I., Schinazi, R. F., Painter, G. R. (2001). Mechanism of Action of 1-{beta}-D-2,6-Diaminopurine Dioxolane, a Prodrug of the Human Immunodeficiency Virus Type 1 Inhibitor 1-{beta}-D-Dioxolane Guanosine. Antimicrob. Agents Chemother. 45: 158-165 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»